Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer

NCT01010945 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.

NCT NCT01010945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01010945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of Erlotinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated Advanced Pancreatic Cancer
Lead sponsor
OSI Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
February 3, 2010
Completion date
January 25, 2012
Enrollment
19 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer